SEC Form 4/A · accession 0001013606-18-000021
ENDOLOGIX INC /DE/ · ELGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
John Onopchenko
Officer — Chief Operating Officer
Period of report
Oct 30, 2017
Accepted (ET)
Mar 1, 2018 · 4:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001013606
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Oct 30, 2017 | A | 56,604 | $0.00 | A | 56,604 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to PurchaseF2,F3 | $5.30 | Oct 30, 2017 | A | 190,353 | A | Oct 30, 2018 | Oct 30, 2027 | Common Shares | 190,353 | 190,353 | D |
Explanation of responses
- F1Performance restricted stock unit award.
- F2Twenty-five percent of the options shall vest upon one year of service and the remaining balance will vest in equal monthly installments thereafter.
- F3On November 1, 2017, the reporting person filed a Form 4 which inadvertently reported that he acquired an option to purchase 187,464 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person acquired an option to purchase 190,353 shares of the issuer's common stock, as originally approved by the issuer's board of directors.